Medivation and Astellas Announce Submission of New Drug Application for ... - MarketWatch (press release)

Medivation and Astellas Announce Submission of New Drug Application for ... MarketWatch (press release) The compound has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy. Pursuant to the Prescription Drug User Fee Act (PDUFA), the FDA is expected to determine within 60 days whether to accept the ... Medivation Submits NDA For EnzalutamideRTT News Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be ...Healthcare Global (press release) all 8 news articles »

Cancer doctors put competition aside to share treatment options for their patients - Washington Post

Cancer doctors put competition aside to share treatment options for their patients Washington Post Over an informal dinner in a Chevy Chase home, 25 doctors peppered one another with questions about prostate cancer treatments and clinical trials. By the end of the meal they had received a real-time, one-stop update. Several promised to refer their ...